NCT00075933View on ClinicalTrials.gov

ARQ 501 in Subjects With Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

September 30, 2003

Primary Completion Date

January 31, 2007

Study Completion Date

January 31, 2007

Conditions
Cancer
Interventions
DRUG

ARQ 501

Trial Locations (2)

75201

Mary Crowley Medical Research Center, Dallas

02115

Dana Farber/Partners CancerCare Inc, Boston

All Listed Sponsors
lead

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

INDUSTRY

NCT00075933 - ARQ 501 in Subjects With Cancer | Biotech Hunter | Biotech Hunter